Rapidly Progressive Glomerulonephritides, Diagnostic and Therapeutic Urgency

1. Glassock R. J., Adler S. G., Ward H. J., et al. Primary glomerular diseases. In: Brenner B. M., Rector F. C., editors. The Kidney. 4th. Philadelphia, Pa, USA: Saunders; 1991. pp. 1182–1279.Search in Google Scholar

2. Moutzouris DA et al, 2009.Search in Google Scholar

3. Davies DJ et al, 1982; van der WoudeFJ et al, 1985; Falk RJ et al, 1988; Jennette JC et al, 1994.24186233Search in Google Scholar

4. Charles Jennette J., Falk R. J., McGregor J. G. Comprehensive Clinical Nephrology. 5th. Elsevier; 2015. Renal and systemic valculitis.Search in Google Scholar

5. Jennette J. C., Olson J. L., Schwartz M. M., Silva F. G. Pauci-immune and ANCA-mediated crescentic glomerulonephritis and vasculitis. Heptinstall’s Pathology of the Kidney. (6th) 2007;1(chapter 14)Search in Google Scholar

6. Watnick S., Dirkx T. Kidney disease. In: Papadakis M. A., McPhee S. J., Rabow M. W., editors. Current Medical Diagnosis & Treatment 2015. New York, NY, USA: McGraw- Hill; 2014.Search in Google Scholar

7. Miloslavsky E.M., Specks U., Merkel P.A. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65:2441–2449. (PubMed)10.1002/art.3804423754238Open DOISearch in Google Scholar

8. de Groot K., Harper L., Jayne D.R. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–680. (PubMed)10.7326/0003-4819-150-10-200905190-00004Search in Google Scholar

9. Hilhorst M., Wilde B., van Paassen P. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)- associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013;28:373–379. (PubMed)10.1093/ndt/gfs428Search in Google Scholar

10. Robson J., Doll H., Suppiah R. Damage in the ANCAassociated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177–184. (PubMed)10.1136/annrheumdis-2013-203927Search in Google Scholar

11. Andreiana I, Stancu S, Avram A, Taran L, Mircescu G: ANCA positive crescentic glomerulonephritis outcome in a Central East Europan cohort: a retrospective study. BMC Nephrol (2015) 15:90.doi:10.1186/s12882-015-0091-8.10.1186/s12882-015-0091-8Open DOISearch in Google Scholar

12. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990;113:656–663. (PubMed)10.7326/0003-4819-113-9-656Search in Google Scholar

13. Pendergraft WF, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med. 2004;10:72–79. (PubMed)10.1038/nm968Search in Google Scholar

14. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3:74–89. (PubMed)10.1038/ki.1973.14Open DOISearch in Google Scholar

15. Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpasture’s disease. Lancet. 2001;358:917–20. (PubMed)10.1016/S0140-6736(01)06077-9Search in Google Scholar

16. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003; 64: 1535–1550 (PubMed)10.1046/j.1523-1755.2003.00241.x12969182Open DOISearch in Google Scholar

17. Kluth DC et al, 1999Search in Google Scholar

18. Cui Z, Zhao J, Jia XY, Zhu SN, Jin QZ, Cheng XY, Zhao MH.: Anti-glomerular basement membrane disease: Outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 90: 303–311, 201110.1097/MD.0b013e31822f6f6821862934Open DOISearch in Google Scholar

19. Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 139–274, 2012Search in Google Scholar

20. Mircescu G, Mandache E, Stancu S –Glomerulopatiile, Editura Enciclopedica, Bucuresti 2016; 973-39-0814-2Search in Google Scholar

21. Salama AD, Dougan T, Levy JB, Cook HT, Morgan SH, Naudeer S, Maidment G, George AJ, Evans D, Lightstone L, Pusey CD.: Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 39: 1162–1167, 200210.1053/ajkd.2002.3338512046026Search in Google Scholar

22. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–192. (PubMed)10.1002/art.17803702068129773Search in Google Scholar

23. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–1177. (PubMed)10.1046/j.1523-1755.2003.00843.x12631105Open DOISearch in Google Scholar

24. Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin Exp Immunol. 1995;101(suppl 1):18–22. (PMC free article) (PubMed)10.1111/j.1365-2249.1995.tb06156.x15535577606854Search in Google Scholar

25. Falk RJ. ANCA-associated renal disease. Kidney Int. 1990;38:998–1010. (PubMed)10.1038/ki.1990.3042266686Open DOISearch in Google Scholar

26. Pettersson EE, Sundelin B, Heigl Z. Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults. Clin Nephrol. 1995;43:141–149. (PubMed).Search in Google Scholar